Jabez Biosciences, Inc., a clinical-stage biopharmaceutical company dedicated to ushering in the future of cancer therapy with their seamless, scalable and synergistic approach, today announced that ...

OCALA, Fla., Aug. 15, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported its financial results for the second quarter 2025.

Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced that it will present at the ...

Streamex is a RWA and gold tokenization company building Institutional grade infrastructure to bring the gold market on chain, enabled by a gold denominated treasury and an institutional grade ...

"Bioxytran is poised to lead the oxygen therapeutics revolution," said Avraham Mayevsky, Member of Bioxytran’s Medical Advisory Board. "The principles in this book, tracing tissue oxygenation, could ...

MARKHAM, Ontario, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ ...

ZURICH, Aug. 15, 2025 (GLOBE NEWSWIRE) -- EAACI has launched its Antibiotic Allergy Awareness Campaign during its 2025 ...

In addition, rYojbaba has granted the underwriters a 45-day option to purchase up to an additional 187,500 Common Shares at the public offering price per share, less the underwriting discount, to ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) approved Tonmya™ (cyclobenzaprine HCl ...

OTTAWA, Ontario, Aug. 15, 2025 (GLOBE NEWSWIRE) -- The Canadian Red Cross has launched the 2025 Newfoundland & Labrador Wildfires Appeal to help people and communities impacted by fires in the ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy ® (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway ...